Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.

Kumar N, Sinha PK, Pandey K, Verma N, Lal CS, Ranjan A, Verma RB, Das P.

Int J Clin Pharm. 2011 Oct;33(5):726-9. doi: 10.1007/s11096-011-9544-8. Epub 2011 Jul 22.

PMID:
21833710
2.

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.

Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.

Lancet. 2011 Feb 5;377(9764):477-86. doi: 10.1016/S0140-6736(10)62050-8. Epub 2011 Jan 20.

PMID:
21255828
3.

Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.

Murray HW.

Future Microbiol. 2010 Sep;5(9):1301-3. doi: 10.2217/fmb.10.92. No abstract available.

4.

Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.

Patole S, Burza S, Varghese GM.

Int J Infect Dis. 2014 Aug;25:204-6. doi: 10.1016/j.ijid.2014.02.015. Epub 2014 Jun 10.

5.

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.

Clin Infect Dis. 2008 Oct 15;47(8):1000-6. doi: 10.1086/591972.

PMID:
18781879
6.

Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.

Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.

Am J Trop Med Hyg. 2009 Mar;80(3):336-8.

PMID:
19270277
7.

Visceral leishmaniasis: elimination with existing interventions.

Matlashewski G, Arana B, Kroeger A, Battacharya S, Sundar S, Das P, Sinha PK, Rijal S, Mondal D, Zilberstein D, Alvar J.

Lancet Infect Dis. 2011 Apr;11(4):322-5. doi: 10.1016/S1473-3099(10)70320-0. Review.

PMID:
21453873
8.

Relapse of kala-azar after use of multiple drugs: a case report and brief review of literature.

Pandey K, Pun SB, Pandey BD.

Indian J Med Microbiol. 2012 Apr-Jun;30(2):227-9. doi: 10.4103/0255-0857.96703. Review.

9.

Combination therapy for visceral leishmaniasis.

van Griensven J, Boelaert M.

Lancet. 2011 Feb 5;377(9764):443-4. doi: 10.1016/S0140-6736(10)62237-4. Epub 2011 Jan 20. No abstract available.

PMID:
21255829
10.

Drug combinations for visceral leishmaniasis.

Olliaro PL.

Curr Opin Infect Dis. 2010 Dec;23(6):595-602. doi: 10.1097/QCO.0b013e32833fca9d. Review.

PMID:
20871400
11.

Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.

Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, Werbovetz KA, Clement JG, Thornton SJ.

J Infect Dis. 2009 Aug 1;200(3):357-60. doi: 10.1086/600105.

PMID:
19545212
12.

Oral miltefosine for Indian visceral leishmaniasis.

Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.

N Engl J Med. 2002 Nov 28;347(22):1739-46.

13.

Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.

Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE.

J Infect. 2006 Jul;53(1):e25-7. Epub 2005 Nov 7.

PMID:
16274744
14.

[Treatment of visceral leishmaniasis in children].

Minodier P, Noël G, Blanc P, Uters M, Retornaz K, Garnier JM.

Med Trop (Mars). 2007 Feb;67(1):73-8. Review. French.

PMID:
17506279
15.

Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.

Olliaro P, Sundar S.

Trop Med Int Health. 2009 Jan;14(1):88-92. doi: 10.1111/j.1365-3156.2008.02195.x. Epub 2008 Dec 11.

16.

Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.

Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, Boelaert M.

PLoS Negl Trop Dis. 2010 Sep 7;4(9). pii: e818. doi: 10.1371/journal.pntd.0000818.

17.
18.

Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.

Marques N, Sá R, Coelho F, Oliveira J, Saraiva Da Cunha J, Meliço-Silvestre A.

Scand J Infect Dis. 2008;40(6-7):523-6. doi: 10.1080/00365540701787800.

PMID:
18584541
19.

Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.

Singh UK, Prasad R, Mishra OP, Jayswal BP.

Indian J Pediatr. 2006 Dec;73(12):1077-80.

PMID:
17202633
20.

Drug resistance in Indian visceral leishmaniasis.

Sundar S.

Trop Med Int Health. 2001 Nov;6(11):849-54. Erratum in: Trop Med Int Health 2002 Mar;7(3):293.

Supplemental Content

Support Center